Upload Avatar (500 x 500)
Hai-Liang Hu
huhl@sustech.edu.cn
English, Chinese
Guangdong
Southern University of Science and Technology
Medical School
  • 1991-1995 Bachelor of Science in Chemistry: Nankai University
  • 1995-2000 Doctor of Science in Biochemistry and Molecular Biology: Shanghai Institute of Biochemistry, Chinese Academy of Sciences
  • Doctoral Supervisor: Academician Hong Guofan
  • Received the Excellent Doctoral Student P&G Award
  • 2001-2007 Postdoctoral Researcher: UCLA School of Medicine
  • 2007-2012 Assistant Researcher: UCLA School of Medicine
  • 2012-2016 Research Assistant Professor: UCLA School of Medicine
  • 2016-2020 Assistant Professor: Duke University School of Medicine
  • 2020- Associate Professor, Associate Researcher: Southern University of Science and Technology School of Medicine
  • 2019 DoD Prostate Cancer Research Program (PCRP) Fund Review Expert
  • 2018 PCF Valor Challenge Award
  • 2011 California Breast Cancer Research Program (BCRP) Young Investigator Award
  • 2003 UCLA JCCF Postdoctoral Research Fellowship Award
  • 2000 Chinese Academy of Sciences Excellent Doctoral P&G Award
DNA damage and repair, tumor metabolism and targeted therapy
Prostate cancer hormone therapy resistance and neuroendocrine small cell carcinoma
Role of non-coding RNA in tumor occurrence, growth, and migration
Development of human induced pluripotent stem cells (hiPSC) for studying neurodegenerative rare diseases
  • An Isoform switch of glutaminase drives therapeutic resistance and disease progression of prostate cancer, Hu H*, Huang J*, 2020
  • N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway, Hu H*, Huang J*, 2019
  • ATM deficiency promotes progression of castration resistant prostate cancer by enhancing Warburg effect, Hu H*, Huang J*, 2019
  • ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response, Hu H*, 2013
  • SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs, Hu H*, Lowry WE*, 2013
  • MicroRNAs: new players in the DNA damage response, Hu H*, 2011
  • ATM is down-regulated by N-Myc-regulated microRNA-421, Hu H*, 2010
  • New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals, Hu H, 2008
  • Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration, Hu H, 2008
  • RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration, Hu H, 2005
  • In Rhizobium leguminosarum, NodD represses its own transcription by competing with RNA polymerase for binding sites, Hu H, 2000
Dna Repair Tumor Metabolism Targeted Therapy Prostate Cancer Hormone Therapy Resistance Neuroendocrine Carcinoma Non-Coding Rna Tumor Migration Hipsc Neurodegenerative Diseases

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.